Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study)
BackgroundMultiple myeloma (MM) is a plasma cell malignancy with significant unmet medical needs, particularly in the treatment of relapsed and refractory disease. This study aims to describe the disease characteristics, various treatment regimens, and outcomes among patients with Relapsed/Refractor...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1547138/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849312262305611776 |
|---|---|
| author | Ayman Alhejazi Ahmad Alhuraiji Abdulnaser Nourallah Abdulrahman Alshehri Binyam Usman Ghada ElGohary Hafiz Malhan Ibraheem Motabi Ibraheem Motabi Khalil Al Farsi Mohammed Alshuaibi Mohanad Diab Mustaqeem Siddiqui Ruba Yasin Taha Tarek Abouzeid Wesam Ahmed Wesam Ahmed Ahmed Ramadan Ali Rasha Ghonema Sana Faysal Elkhazin Yousra Moussa Abdullah M. Alrajhi Abdullah M. Alrajhi Magdy Rabea Yahia Aktham Nesreen Bawazeer Ali Ahmed Ali Mohamed Zahir Chouikrat |
| author_facet | Ayman Alhejazi Ahmad Alhuraiji Abdulnaser Nourallah Abdulrahman Alshehri Binyam Usman Ghada ElGohary Hafiz Malhan Ibraheem Motabi Ibraheem Motabi Khalil Al Farsi Mohammed Alshuaibi Mohanad Diab Mustaqeem Siddiqui Ruba Yasin Taha Tarek Abouzeid Wesam Ahmed Wesam Ahmed Ahmed Ramadan Ali Rasha Ghonema Sana Faysal Elkhazin Yousra Moussa Abdullah M. Alrajhi Abdullah M. Alrajhi Magdy Rabea Yahia Aktham Nesreen Bawazeer Ali Ahmed Ali Mohamed Zahir Chouikrat |
| author_sort | Ayman Alhejazi |
| collection | DOAJ |
| description | BackgroundMultiple myeloma (MM) is a plasma cell malignancy with significant unmet medical needs, particularly in the treatment of relapsed and refractory disease. This study aims to describe the disease characteristics, various treatment regimens, and outcomes among patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the Greater Gulf region.MethodsA regional, retrospective study was conducted in Gulf countries to collect real-world data from the medical records of 148 patients with RRMM who relapsed 1–3 times in the past two years before the data collection period (July 2022 and February 2023).ResultsThe mean age of the study population was 59.4 years, and 64.2% of the participants were male. The VRd regimen (Bortezomib, Lenalidomide, and Dexamethasone) was the most frequent first-line therapy among transplant-ineligible patients (40.2%) and the most common induction and consolidation regimen (43.9% and 66.7%, respectively) in transplant-eligible patients. Meanwhile, Rd (Lenalidomide and Dexamethasone) was the most common maintenance regimen (75%). DKd (Daratumumab, Carfilzomib, and Dexamethasone), KPd (Carfilzomib, Pomalidomide, and Dexamethasone), and PVd (Pomalidomide, Bortezomib, and Dexamethasone) were the most widely used second, third, and fourth treatment lines, respectively (16.6%, 9.2%, and 12.5%). About 52.7% of patients were eligible for stem cell transplantation (SCT), and among them, a complete response (CR) was achieved in 47.7%. Furthermore, CR and very good partial remission rates decreased across all treatment lines. Renal impairment decreased across different treatment lines, from 23.6% in the first line to 6.3% in the fourth line. In contrast, respiratory complications demonstrated the highest incidence (>18%) in the 3rd and 4th treatment lines. Moreover, refractoriness to treatment increased from 1.3% in the first line to 34.6% in the fourth treatment line. Additionally, isatuximab was incorporated into 80%, 15%, and 5% of the regimens administered as second-, third-, and fourth-line treatments, respectively.ConclusionThis study provides valuable insights into the real-world management and treatment choices for RRMM, including the utilization of SCT and novel therapies such as isatuximab. |
| format | Article |
| id | doaj-art-b0bbb5c84da2401f8771dd79a2602c4f |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-b0bbb5c84da2401f8771dd79a2602c4f2025-08-20T03:53:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-05-011510.3389/fonc.2025.15471381547138Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study)Ayman Alhejazi0Ahmad Alhuraiji1Abdulnaser Nourallah2Abdulrahman Alshehri3Binyam Usman4Ghada ElGohary5Hafiz Malhan6Ibraheem Motabi7Ibraheem Motabi8Khalil Al Farsi9Mohammed Alshuaibi10Mohanad Diab11Mustaqeem Siddiqui12Ruba Yasin Taha13Tarek Abouzeid14Wesam Ahmed15Wesam Ahmed16Ahmed Ramadan Ali17Rasha Ghonema18Sana Faysal Elkhazin19Yousra Moussa20Abdullah M. Alrajhi21Abdullah M. Alrajhi22Magdy Rabea23Yahia Aktham24Nesreen Bawazeer25Ali Ahmed Ali26Mohamed Zahir Chouikrat27Division of Adult Hematology, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi ArabiaDepartment of Hematology, Kuwait Cancer Control Center, Kuwait, KuwaitHematology/Medical Oncology Department, Almana General Hospital, Alkhobar, Saudi ArabiaHematology/Oncology Department, Aseer Central Hospital, Abha, Saudi ArabiaDepartment of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi ArabiaDepartment of Medicine, Division of Oncology/Hematology, College of Medicine, King Saud University Medical City, Riyadh, Saudi ArabiaDepartment of Adult Hematology, Prince Mohammed bin Nasser Hospital, Jazan, Saudi ArabiaAdult Hematology and Bone Marrow Transplant Department, Comprehensive Cancer Center at King Fahad Medical City, Riyadh, Saudi ArabiaAdult Hematology Department, Alfaisal University, Riyadh, Saudi Arabia0Department of Hematology, Sultan Qaboos University Hospital, Muscat, Oman1Adult Hematology and Oncology Divisions, Department of Medicine, King Abdul-Aziz Hospital, Alahsa, Saudi Arabia2Hemato-oncology Department, Burjeel Hospital, Abu Dhabi, United Arab Emirates3Hematology and Oncology Division at Sheikh Shakhbout Medical City (SSMC), Abu Dhabi, United Arab Emirates4Department of Hematology-Bone Marrow Transplantation, National Centre for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha, Qatar5Internal Medicine Department, Almouwasat Hospital, Dammam, Saudi Arabia6Oncology Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates7Oncology Institute, Cleveland Clinic Florida, Florida, FL, United StatesHematology/Medical Oncology Department, Almana General Hospital, Alkhobar, Saudi ArabiaDepartment of Hematology, Kuwait Cancer Control Center, Kuwait, Kuwait2Hemato-oncology Department, Burjeel Hospital, Abu Dhabi, United Arab EmiratesHematology/Medical Oncology Department, Almana General Hospital, Alkhobar, Saudi Arabia8Clinical Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia9Department of Pharmacy Practice, College of Pharmacy, AlFaisal University, Riyadh, Saudi Arabia0Medical Affairs Department, Sanofi, Jeddah, Saudi Arabia0Medical Affairs Department, Sanofi, Jeddah, Saudi Arabia0Medical Affairs Department, Sanofi, Jeddah, Saudi Arabia1Medical Affairs Department, Sanofi, Dubai, United Arab Emirates1Medical Affairs Department, Sanofi, Dubai, United Arab EmiratesBackgroundMultiple myeloma (MM) is a plasma cell malignancy with significant unmet medical needs, particularly in the treatment of relapsed and refractory disease. This study aims to describe the disease characteristics, various treatment regimens, and outcomes among patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the Greater Gulf region.MethodsA regional, retrospective study was conducted in Gulf countries to collect real-world data from the medical records of 148 patients with RRMM who relapsed 1–3 times in the past two years before the data collection period (July 2022 and February 2023).ResultsThe mean age of the study population was 59.4 years, and 64.2% of the participants were male. The VRd regimen (Bortezomib, Lenalidomide, and Dexamethasone) was the most frequent first-line therapy among transplant-ineligible patients (40.2%) and the most common induction and consolidation regimen (43.9% and 66.7%, respectively) in transplant-eligible patients. Meanwhile, Rd (Lenalidomide and Dexamethasone) was the most common maintenance regimen (75%). DKd (Daratumumab, Carfilzomib, and Dexamethasone), KPd (Carfilzomib, Pomalidomide, and Dexamethasone), and PVd (Pomalidomide, Bortezomib, and Dexamethasone) were the most widely used second, third, and fourth treatment lines, respectively (16.6%, 9.2%, and 12.5%). About 52.7% of patients were eligible for stem cell transplantation (SCT), and among them, a complete response (CR) was achieved in 47.7%. Furthermore, CR and very good partial remission rates decreased across all treatment lines. Renal impairment decreased across different treatment lines, from 23.6% in the first line to 6.3% in the fourth line. In contrast, respiratory complications demonstrated the highest incidence (>18%) in the 3rd and 4th treatment lines. Moreover, refractoriness to treatment increased from 1.3% in the first line to 34.6% in the fourth treatment line. Additionally, isatuximab was incorporated into 80%, 15%, and 5% of the regimens administered as second-, third-, and fourth-line treatments, respectively.ConclusionThis study provides valuable insights into the real-world management and treatment choices for RRMM, including the utilization of SCT and novel therapies such as isatuximab.https://www.frontiersin.org/articles/10.3389/fonc.2025.1547138/fullmultiple myelomarelapsed/refractoryGulf Regionreal-worldisatuximab |
| spellingShingle | Ayman Alhejazi Ahmad Alhuraiji Abdulnaser Nourallah Abdulrahman Alshehri Binyam Usman Ghada ElGohary Hafiz Malhan Ibraheem Motabi Ibraheem Motabi Khalil Al Farsi Mohammed Alshuaibi Mohanad Diab Mustaqeem Siddiqui Ruba Yasin Taha Tarek Abouzeid Wesam Ahmed Wesam Ahmed Ahmed Ramadan Ali Rasha Ghonema Sana Faysal Elkhazin Yousra Moussa Abdullah M. Alrajhi Abdullah M. Alrajhi Magdy Rabea Yahia Aktham Nesreen Bawazeer Ali Ahmed Ali Mohamed Zahir Chouikrat Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study) Frontiers in Oncology multiple myeloma relapsed/refractory Gulf Region real-world isatuximab |
| title | Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study) |
| title_full | Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study) |
| title_fullStr | Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study) |
| title_full_unstemmed | Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study) |
| title_short | Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study) |
| title_sort | analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments a retrospective real world registry study in the greater gulf region repair study |
| topic | multiple myeloma relapsed/refractory Gulf Region real-world isatuximab |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1547138/full |
| work_keys_str_mv | AT aymanalhejazi analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT ahmadalhuraiji analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT abdulnasernourallah analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT abdulrahmanalshehri analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT binyamusman analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT ghadaelgohary analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT hafizmalhan analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT ibraheemmotabi analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT ibraheemmotabi analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT khalilalfarsi analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT mohammedalshuaibi analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT mohanaddiab analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT mustaqeemsiddiqui analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT rubayasintaha analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT tarekabouzeid analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT wesamahmed analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT wesamahmed analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT ahmedramadanali analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT rashaghonema analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT sanafaysalelkhazin analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT yousramoussa analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT abdullahmalrajhi analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT abdullahmalrajhi analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT magdyrabea analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT yahiaaktham analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT nesreenbawazeer analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT aliahmedali analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy AT mohamedzahirchouikrat analysisofpharmacotherapeuticapproachesformultiplemyelomaandcorrelatedrenalandpulmonaryimpairmentsaretrospectiverealworldregistrystudyinthegreatergulfregionrepairstudy |